AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03220308 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care-as-usual for children (8-16 years old) with ADHD
Description: According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
Study NCT03220308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care-as-usual for children (8-16 years old) with ADHD
Description: According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
Study NCT01436734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting glycemia
Description: no intervention
Study NCT01436734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia
Description: Insulin induced hypoglycemia
Study NCT00783276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO
Study NCT01431495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pidogrel
Description: Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
Study NCT01431495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix
Description: Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
Study NCT05141851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implants with 0,7 mm threads
Description: Implants were placed, with threads of 0.7 mm in the location of premolars and molars.
Study NCT05141851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implants with 0.3 mm threads
Description: Implants were placed, with threads of 0.3 mm in the location of premolars and molars.
Study NCT05083390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: norUrsodeoxycholic acid
Description: 500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
Study NCT05083390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norUrsodeoxycholic acid
Description: 500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
Study NCT02643875 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Orthokeratology
Description: It is a kind of rigid permeable lens.
Study NCT02643875 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology
Description: It is a kind of rigid permeable lens.
Study NCT00975936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK706769
Description: 50µg \[14C\]-GSK706769 containing 250 nCi
Study NCT01882543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125
Description: Synthetic SHIP1 activator
Study NCT01882543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind placebo capsule
Study NCT01621308 — intervention group
Intervention type: OTHER
Intervention: Mode of insulin administration
Description: There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
Study NCT00890695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready to use supplementary food (RUSF)
Description: It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
Study NCT03395977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Lactose placebo for pills and saline for perfusion.
Study NCT03395977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Lactose placebo for pills and saline for perfusion.
Study NCT03395977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat tablet.
Study NCT03395977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Rasburicase injectable solution.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotablator
Description: Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
Study NCT01887704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional angioplasty
Description: Conventional angioplasty was used in both arms.
Study NCT01887704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional angioplasty
Description: Conventional angioplasty was used in both arms.
Study NCT01887704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stenting
Description: Stenting was implanted in both arms.
Study NCT01887704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stenting
Description: Stenting was implanted in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting balloon
Description: Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutting balloon
Description: Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
Study NCT01887704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin will be administrated in participants in both arms.
Study NCT01887704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin will be administrated in participants in both arms.
Study NCT01887704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel will be administrated to participants in both arms.
Study NCT01887704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel will be administrated to participants in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent
Description: Paclitaxel-eluting stent will be used in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Description: Paclitaxel-eluting stent will be used in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zotarolimus-eluting stent
Description: Zotarolimus-eluting stent will be implanted in participants in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zotarolimus-eluting stent
Description: Zotarolimus-eluting stent will be implanted in participants in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent will be used in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent will be used in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent will be used in both arms.
Study NCT01887704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent will be used in both arms.
Study NCT01702324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DD-25
Description: A topical DD-25 cream at 0.025% concentration.
Study NCT01732822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
Study NCT01732822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
Study NCT02125045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-GSH
Description: Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.
Study NCT02125045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared using the same excipients of the dietary supplement without active substance.
Study NCT00129480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistance with Pain treatment
Description: Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
Study NCT02655068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET/CT
Description: Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings.
Study NCT02655068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Computed Tomography (CT)
Description: Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings
Study NCT02862587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02862587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02862587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: precision cells
Description: precision cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT03164694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib was given 850 mg per day orally.
Study NCT03164694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed (500 mg/m2)
Study NCT03164694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: pemetrexed (500 mg/m2)
Study NCT03164694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin (AUC =5)
Study NCT03164694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin (AUC =5)
Study NCT03002220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radium-223
Description: Radium-223 at a dose of 55 kBq
Study NCT04523675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.
Study NCT04523675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.
Study NCT04523675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.
Study NCT04523675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.
Study NCT03486860 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Psychoeducation
Description: 6-session parent psychoeducation group on child anxiety, following their children's lead, and encouraging approach behaviors.
Study NCT03486860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Turtle Program
Description: The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
Study NCT00128102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 100 mg oral capsules
Study NCT00128102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vorinostat-matching placebo oral capsules
Study NCT02666144 — intervention group
Intervention type: DEVICE
Intervention: Spectralis OCT
Description: Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
Study NCT02225132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.~The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium.
Study NCT03599258 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Skylife
Description: Newly FDA approved device
Study NCT03599258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Both devices are considered standard therapy
Study NCT02084563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Induction Chemotherapy
Description: Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~* Cytarabine 200 mg/m2 IV continuous infusion days 1-7~* Daunorubicin 90 mg/m2 intravenous piggyback days 1-3
Study NCT02084563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation Chemotherapy
Description: Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles
Study NCT00975936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 200 mg Ketoconazole (Q12)
Study NCT04655417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Tetradecyl Sulfate
Description: DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
Study NCT02125552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
Study NCT02125552 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional intravenous access
Description: Placement by experienced nurse using standard IV techniques
Study NCT02084563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Autologous Stem Cell Transplantation
Description: Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2
Study NCT02084563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4
Study NCT02084563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Low Dose Cytarabine
Description: Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~* Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)
Study NCT02084563 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~* Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)
Study NCT02371291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Flexibility Training
Description: As in experimental arm description.
Study NCT02371291 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: As in experimental arm description.
Study NCT03171662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Pediatric Appendicitis Score
Description: Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
Study NCT04284605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with strength training
Description: 30 minute aerobic exercise training with warm-up and cool down followed by 30 minute strength training for specific muscles.
Study NCT04284605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 60 minute yoga intervention including different asanas, breath control and meditation
Study NCT02683551 — intervention group
Intervention type: PROCEDURE
Intervention: Sutureless Thyroidectomy
Description: Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
Study NCT04285398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmic examinations
Description: Slit-lamp examination, IntraOcular Pressure, Visual Acuity, Visual Field, Full-field Stimulus Threshold, Dark adaptometry, Color Vision testing, Optical Coherence Tomography, Fundus AutoFluorescence and Adaptive Optics imaging.
Study NCT04285398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobility Test
Description: Functional test to evaluate mobility and postural condition of patients
Study NCT04143945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Study NCT04143945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by PDS290 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Study NCT02566044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02566044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW276
Description: 0.3 mg and 1.5 mg strengths